Valneva SE: Market Leadership of Selected Vaccines Impresses Investors!
Reading Time: 2 minutes
Valneva SE (i.) is a specialized biotechnology company focused on the development and marketing of vaccines against infectious diseases. Valneva's commercial portfolio includes three main vaccines: IXIARO against Japanese Encephalitis, DUKORAL for the prevention of Cholera, and IXCHIQ, the world's first approved vaccine against Chikungunya. The company's market leadership has contributed, amongst other things, to the U.S. Department of Defense ordering the Japanese Encephalitis vaccine for $32.8 million. Additionally, the recent Chikungunya outbreak...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
